Shopping Cart
- Remove All
Your shopping cart is currently empty
ANI-7
🥰Excellent
Catalog No. T10325Cas No. 931417-26-4
ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM).
ANI-7
🥰Excellent
Purity: 99.21%
Catalog No. T10325Cas No. 931417-26-4
ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $34 | In Stock | |
| 10 mg | $59 | In Stock | |
| 25 mg | $113 | In Stock | |
| 50 mg | $188 | In Stock | |
| 100 mg | $287 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ANI-7"
Prexasertib
LY2606368
T43101234015-52-1
Prexasertib (LY2606368) is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
- $48
Size
QTY
Baricitinib
Cited
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
- $43
Size
QTY
CitedPD0166285
PD-166285
T6931185039-89-8
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
- $52
Size
QTY
CHK1-IN-3
T107912097252-39-4In house
CHK1-IN-3 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 0.4 nM).
- $195
Size
QTY
CHK1-IN-4 hydrochloride
CHK1-IN-4 hydrochloride（2120398-41-4 Free base）
T10792LIn house
CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1). CHK1-IN-4 hydrochloride potently inhibits chk1 phosphorylation in the tumor cells. CHK1-IN-4 hydrochloride has anti-tumor activity.
- $197
Size
QTY
Rabusertib Cited
LY2603618, IC-83
T6084911222-45-2
Rabusertib (IC-83) is an inhibitor of the cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiating activity. Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non-Small Cell Lung Cancer.
- $38
Size
QTY
CitedPrexasertib dihydrochloride
Prexasertib 2HCl, LY2606368 2HCl, LY2606368 (dihydrochloride)
T43271234015-54-3
Prexasertib dihydrochloride (LY2606368) is an ATP-competitive CHK1 inhibitor (Ki: 0.9 nmol/L). in the cell-free assay, its IC50 values are 8 nM and 9 nM for CHK2 and RSK, respectively.
- $38
Size
QTY
CCT245737 Cited
SRA737
T70801489389-18-5
CCT245737 is an orally active, selective Chk1 inhibitor with an IC50 of 1.3 nM, and is >1,000-fold selective over CHK2 and CDK1.
- $33
Size
QTY
CitedA-443654
T14072552325-16-3
A-443654, a pan-Akt inhibitor, exhibits equal potency against Akt1, Akt2, and Akt3 within cells (Ki=160 pM).
- $84
Size
QTY
BML-277 Cited
Chk2 Inhibitor II, C 3742, BML 277
T2033516480-79-8
BML-277 (C 3742) is a selective checkpoint kinase 2 (Chk2) inhibitor.
- $47
Size
QTY
CitedSelect Batch
Purity:99.21%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM). |
| In vitro | ANI-7 (2.5 μM; 24 hours; MCF10A and MDA-MB-468 cells) treatment induces significant S-phase and G2 + M-phase cell cycle arrest within 24 hours in MDA-MB-468 cells. ANI-7 (2 μM; 12-24 hours; MDA-MB-468 cells) significantly increases CHK2 content and phosphorylation and induces a significant increase in H2AXɣ, indicating DNA double-strand damage. GI50 values show ANI-7 has a GI50 of 0.38 μM in MCF-7 cells, while values of 3.0-42 μM are seen in lung, colon, ovary, neuronal, glial, prostate, and pancreas cell lines. The A431 vulva cell line shows appreciable growth inhibition (GI50 of 0.51 μM) by ANI-7. ANI-7 potently inhibits T47D, ZR-75-1, MCF-7, SKBR3, and MDA-MB-468 breast cancer cells (GI50 range 0.16-0.38 μM), moderately inhibits BT20 and BT474 cells (GI50 range 1-2 μM), and essentially fails to inhibit MDA-MB-231 and MCF10A cells (GI50 range 17-26 μM). Additionally, ANI-7 maintains its inhibitory effect on drug-resistant cells (MCF-7/VP16: GI50 of 0.21 μM) [1]. |
| Molecular Weight | 263.12 |
| Formula | C13H8Cl2N2 |
| Cas No. | 931417-26-4 |
| Smiles | Clc1ccc(cc1Cl)C(=C\c1ccc[nH]1)\C#N |
| Relative Density. | 1.398 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (171.02 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ANI-7 | purchase ANI-7 | ANI-7 cost | order ANI-7 | ANI-7 chemical structure | ANI-7 in vitro | ANI-7 formula | ANI-7 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.